Completed Human Clinical Trials:
- BIT225-001 – Phase 1, single-dose, dose escalating study (n=48)
- BIT225-003 – Phase 1b, HCV-infected patients (n=18)
- BIT225-004 – Phase 1b/2a, HIV-1 infected patients (n=21) Trial registration on ANZCTR
- BIT225-005 – Phase 2a, HCV-infected patients (n=24) Trial registration on ANZCTR
- BIT225-006 – Phase 2, HIV/HCV co-infected (n=12) Trial registration on ANZCTR
- BIT225-007 – Phase 1 capsule formulation, cross-over study (n=14) Trial registration on ANZCTR
- BIT225-008 – Phase 2, repeat dose (n=60) Trial registration on ANZCTR